Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients

Diseases of the Colon and Rectum

Volumn 47, Issue 7, 2004, Pages 1216-1224

  Gal, Rivka ^a,c   Sadikov, Evgeny ^a   Sulkes, Jaqueline ^b,c   Klein, Baruch ^a,c   Koren, Rumelia ^a,c  

^a HASHARON HOSPITAL   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemotherapy; Chromosome 18q; Colorectal cancer; Prognosis

Indexed keywords

DELETED IN COLORECTAL CANCER PROTEIN; FLUOROURACIL; LEVAMISOLE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DELETED IN COLORECTAL CANCER GENE; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION;

EID: 3042782851     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10350-004-0552-9     Document Type: Article

References (47)

1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
3. Nauta R, Stablein DM, Holyoke ED. Survival of patients with stage B2 colon carcinoma. The gastrointestinal tumor study group experience. Arch Surg 1989;124:180-2.
4. Moertel CG, Fleming TR, Macdonald JS, et al. Inter-group study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13:2936-43.
5. Mortel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330:1136-42.
6. Witzig TE, Loprinzi CL, Gonchoroff NJ, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stage B2 colorectal adenocarcinoma. Cancer 1991;68:879-88.
7. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancer. Science 1990;247:49-56.
8. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
9. Martinez-Lopez E, Abad A, Font A, et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998;114:1180-7.
10. Jernvall P, Makinen MJ, Karttunen TJ, Makela J, Vihko P. Loss of heterozygosity of 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999;79:903-8.
11. Kato M, Ito Y, Kobayashi S, Isono K. Detection of DCC and Ki-ras gene alteration in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 1996;77:1729-35.
12. Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996;335:1727-32.
13. Saito M, Yamaguchi A, Goi T, et al. Expression of DCC protein in colorectal tumors and its relation to tumor progression and metastases. Oncology 1999;56:134-41.
14. Reymond MA, Dworak O, Remke S, Hohenberger W, Kirchner T, Kockerling F. DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 1998;41:755-60.
15. Schmitt CA, Thaler KR, Witting BM, Kaulen H, Buschenfelde KH, Dippold WG. Detection of the DCC gene product in normal and malignant colorectal tissues and its relation to codon 201 mutation. Br J Cancer 1998;77:588-94.
16. Shibata D, Rieger RM, Hess D, Summerhayes JC, Steele G. Disruption of DCC expression results in the acquisition of metastatic cell behavior. Surg Forum 1995;46:526-7.
17. Jessup JM, Loda M. Prognostic markers in rectal carcinoma. Semin Surg Oncol 1998;15:131-40.
18. Sobin LH, Wittekind CH. TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss, 1997:66-73.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
20. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34:187-220.
21. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525-32.
22. Horstmann MA, Posl M, Scholz RB, et al. Frequent reduction or loss of DCC gene expression in human osteosarcoma. Br J Cancer 1997;75:1309-17.
23. Kong XT, Choi SH, Inoue A, et al. Alterations of the tumor suppressor gene DCC in neuroblastoma. Eur J Cancer 1997;33:1962-5.
24. Yoshida Y, Itoh F, Endo T, Hinoda Y, Imai K. Decreased DCC mRNA expression in human gastric cancer is clinicopathologically significant. Int J Cancer 1998;79:634-40.
25. Saegusa M, Hashimura M, Hara A, Okayasu I. Loss of expression of the gene deleted in colon carcinoma (DCC) is closely related to histologic differentiation and lymph node metastasis in endometrial carcinoma. Cancer 1999;85:453-64.
26. Wakita K, Kohno N, Sakoda Y, Ishikawa Y, Sakaue M. Decreased expression of the DCC gene in human breast carcinoma. Surg Today 1996;26:900-3.
27. Carthers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR. Prognosis of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998;114:1188-95.
28. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
29. Banerjee AK. DCC expression and prognosis in colorectal cancer. Lancet 1997;349:968.
30. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE. The DCC gene product induces apoptosis by mechanisms requiring receptor proteolysis. Nature 1998;395:801-4.
31. Samagura K, Makino M, Shirai H, et al. Enhanced induction of apoptosis in human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. Cancer 1997;79:12-27.
32. Schepotin IB, Soldatenkov V, Buras RR, Nauta RJ, Shabahang M, Evans SR. Apoptosis of human primary and metastatic colon adenocarcinoma cell lines in vitro induced by 5-fluorouracil, verapamil and hyperthermia. Anticancer Res 1994;14:1207-31.
33. Koshiji M, Taketani S, Takeuchi K, Hioki K, Ikehara S. Mechanisms underlying apoptosis induced by combination of 5-fluorouracil and interferon-gamma. Biochem Biophys Res Commun 1997;240:376-81.
34. Inada T, Ichikawa A, Kubota T, Ogata Y, Moossa AR, Hoffman RM. 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Res 1997;17:1965-71.
35. Artwohl M, Holzenbein T, Wagner L, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM. Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol 2000;131:1577-83.
36. Mader RM, Muller M, Stenger GG. Resistance to 5-fluorouracil. Gen Pharmacol 1998;31:661-6.
37. Greif R, Swallow C, Bapat B, Redsron M, Gallinger S, Couture L. Molecular biology of colorectal cancer. Curr Probl Cancer 1997;21:233-300.
38. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206.
39. Lenz HJ, Daneberg KD, Leichman CG, et al. p53 and thymidylate syntheses expression in untreated stage II colon cancer: association with recurrence, survival and site. Clin Cancer Res 1998;4:1227-34.
40. Leichman L, Lenz HJ, Leichman CG, et al. Quantitation of intratumoral thymidylate synthesis expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 1995;31A:1306-10.
41. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidilate syntheses gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
42. Benhatter J, Cerottini JP, Saraga E, Mettez G, Givel JC. p53 mutations as possible predictor of response to chemotherapy in colorectal carcinomas. Int J Cancer 1996;69:190-2.
43. Furham GM, Talamonti MS, Curley SA. Spincter-preserving extended resection for locally advanced rectosigmoid carcinoma involving the urinary bladder. J Surg Oncol 1992;50:77-80.
44. Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001;6:81-91.
45. Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998;25:39-46.
46. Gerard B, Bleiberg H, VanDaele D, et al. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs 1998;9:301-5.
47. Van Cutsem E. A glimpse of the future. New directions in the treatment of colorectal cancer. Eur J Cancer 1996;32A:S23-7.